Esreboxetine
chemical compound
Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor. It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.
Esreboxetine was developed by Pfizer for the treatment of neuropathic pain and fibromyalgia. It failed to show significant benefit over currently available medications and was discontinued. A subsequent 2012 study (n=277) found esreboxetine gave significant reductions in pain and fatigue in fibromyalgia patients.
The public source identifies “Esreboxetine” as chemical compound. This brief keeps that definition visible, then builds a research path around Esreboxetine, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Esreboxetine”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 14, 2026. The linked authority identifier is Q5399299. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2012.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Esreboxetine”, its source revision and the description used here.
- Expand the search: follow Esreboxetine primary sources, Esreboxetine archive and Esreboxetine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Esreboxetine”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Esreboxetine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.